Hantz Financial Services Inc. Invests $9.26 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hantz Financial Services Inc. purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 161,772 shares of the biopharmaceutical company's stock, valued at approximately $9,260,000. Hantz Financial Services Inc. owned about 0.13% of Halozyme Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of HALO. Swedbank AB bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $13,927,000. Boston Partners increased its holdings in shares of Halozyme Therapeutics by 14.1% in the 1st quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company's stock valued at $25,500,000 after acquiring an additional 77,976 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Halozyme Therapeutics by 9.8% during the first quarter. DekaBank Deutsche Girozentrale now owns 54,907 shares of the biopharmaceutical company's stock worth $2,220,000 after purchasing an additional 4,907 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 254 shares during the period. Finally, First Hawaiian Bank increased its stake in Halozyme Therapeutics by 10.5% during the second quarter. First Hawaiian Bank now owns 5,571 shares of the biopharmaceutical company's stock valued at $292,000 after purchasing an additional 530 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total value of $525,800.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $35,583,199.52. This represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 60,000 shares of company stock worth $3,425,000 in the last 90 days. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $0.27 on Friday, hitting $48.20. The company's stock had a trading volume of 720,988 shares, compared to its average volume of 1,372,477. The company has a market capitalization of $6.13 billion, a price-to-earnings ratio of 15.96, a price-to-earnings-growth ratio of 0.44 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The stock's 50-day moving average is $53.28 and its two-hundred day moving average is $53.67.

Wall Street Analyst Weigh In

HALO has been the subject of several research reports. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. TD Cowen upped their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Benchmark reiterated a "buy" rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Morgan Stanley boosted their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.